Calumet director Jennifer Straumins sells shares worth $2.38 million

Calumet Inc. (CLMT) director Jennifer Straumins sold 150,000 shares in two transactions on June 13th and 16th for a total of approximately $2.38 million, retaining 934,589 shares; this follows a recent earnings miss of -$1.87 EPS versus the projected -$0.38, despite revenue exceeding expectations at $993.9 million. BofA Securities initiated coverage on CLMT with a Buy rating and a $15 price target, citing the company's biofuel business and MaxSAF project, which could double EBITDA between 2025 and 2027.

Analysis

Calumet Inc. (CLMT) presents a complex scenario characterized by recent insider selling, strong short-term stock performance, mixed Q1 2025 financial results, and a positive long-term outlook from at least one analyst. Director Jennifer Straumins sold 150,000 shares across two transactions at $15.08 and $16.23 per share, totaling approximately $2.38 million, though she retains 934,589 shares. This occurred as CLMT's stock, currently trading at $16.86, surged nearly 21% in the past week, leading to an 'overbought' indication from InvestingPro. The company's Q1 2025 earnings per share of -$1.87 significantly missed the projected -$0.38, while revenue of $993.9 million surpassed the $919.3 million forecast. Contrasting these immediate financial signals, BofA Securities initiated coverage with a 'Buy' rating and a $15 price target, which is below the current trading price, citing substantial growth potential from Calumet's biofuel business and its MaxSAF project, anticipated to potentially double EBITDA between 2025 and 2027. Calumet, valued at $1.46 billion and rated 'Fair' by InvestingPro, also recently received shareholder approval for executive compensation and director elections, indicating ongoing support for its strategic direction.

Key Decisions for Investors

• Investors should weigh the director's recent share sales, occurring amidst a rapid stock price increase to $16.86 and an 'overbought' signal, against the company's long-term growth narrative.
• Carefully consider the significant Q1 2025 earnings miss (EPS -$1.87) alongside the better-than-expected revenue ($993.9 million) and BofA Securities' $15 price target, which suggests potential valuation concerns at current levels despite a 'Buy' rating.
• Monitor the progress of the MaxSAF project and subsequent earnings reports for validation of the projected EBITDA growth, as these will be key to reconciling the current mixed signals and justifying the stock's valuation.